Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.37 |
| ▸ | VDR | P11473 | 5/20 | 0.35 |
| ▸ | KLF10 | Q13118 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 2/20 | 0.31 |
| ▸ | BACE1 | P56817 | 2/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.31 |
| ▸ | SHBG | P04278 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25846223 | 0.83 | ESR1 (0.35) | ESR1ESR2VDRKLF10ACE2 | |
| SCHEMBL25846208 | 0.83 | ESR1 (0.35) | ESR1ESR2VDRKLF10ACE2 | |
| SCHEMBL25751730 | 0.80 | ESR1 (0.48) | ESR1ESR2VDRKLF10ACE2 | |
| SCHEMBL10916780 | 0.77 | ESR1 (0.48) | ESR1ESR2ATMEPHX2 | |
| SCHEMBL25846204 | 0.77 | SLC6A2 (0.47) | ESR1VDRKLF10ACE2SHBG | |
| SCHEMBL10914831 | 0.76 | HRH3 (0.38) | ESR1ESR2ATM | |
| SCHEMBL10916864 | 0.74 | ATM (0.53) | ESR1ESR2ATM | |
| SCHEMBL12416184 | 0.72 | ENPP2 (0.43) | VDRSHBG | |
| SCHEMBL10915580 | 0.71 | ESR1 (0.44) | ESR1ESR2 | |
| SCHEMBL8566624 | 0.70 | DRD2 (0.47) | ESR1ESR2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702383-B2 | Methods for producing D-α-methyldopa | IMMUNOMOLECULAR THERAPEUTICS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702383-B2 | Methods for producing D-α-methyldopa | AMPD2, AMPD3, AMPD1 | ESR1 3494/4885ESR2 2322/4885VDR 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.